TransCode Engages Advisor to Evaluate Strategic Alternatives for Oncology Portfolio
TransCode Therapeutics, Inc. announced the initiation of a formal strategic process led by Tungsten Advisors to explore potential transactions for its oncology portfolio, including its lead candidate TTX-MC138. The actions suggest the company is seeking to maximize value with no plans to continue funding the development of its lead asset.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed